Pharvaris price target lowered to $51 from $52 at RBC Capital

RBC Capital lowered the firm’s price target on Pharvaris (PHVS) to $51 from $52 and keeps an Outperform rating on the shares after its Q4 results. The firm continues to believe that the company has a high-quality asset in deucrictibant, adding that both IR and XR formulations could capture significant market share across the hereditary angioedema treatment spectrum given strong efficacy, clean safety, and oral convenience that should help it differentiate from other more entrenched players, the analyst tells investors in a research note.